#financial results #Ireland #Dublin #Perrigo Company #Self-Care Products

Perrigo Reports Third Quarter 2026 Financial Results

Perrigo Company plc (NYSE: PRGO), a significant player in the consumer self-care product market, has recently announced its financial outcomes for the third quarter ending on September 26, 2026. According to Albert Manzone, the Interim President and CEO, the execution of the company's Three-S plan is yielding positive results in various business segments, highlighted by an increase in market share within U.S. store brand OTC products as well as key brands in Europe.

Strategic Overview

The company's recent decision to divest its Infant Formula line is a pivotal change, positioning Perrigo to concentrate on higher-margin self-care categories. This shift is part of a broader strategy to streamline operations and enhance profitability. The divestiture is expected to simplify Perrigo's portfolio significantly, allowing the company to focus on areas that promise better returns.

In light of these business changes, the company has adjusted its full-year outlook. The revised expectations account for a more conservative stance regarding retailer inventory ahead of the season, in addition to ongoing softness observed in the European market.

Financial Highlights

For the third quarter, Perrigo reported:

• - Net Sales: $989 million, down 5.2% compared to the previous year’s $1.043 billion.
• - Gross Margin: 32.4%, reflecting a decrease of 370 basis points.
• - Operating Margin: 2.3%, declining by 460 basis points.
• - Diluted EPS: $(0.10), versus earnings of $0.09 for the prior year.

Core net sales reflected a year-over-year decrease of 1.7%, largely due to lower consumption trends in the Self Care segment, which warranted a conservative inventory approach ahead of the cough and cold season. Notably, performance was impacted by reduced contract manufacturing volumes.

Despite these challenges, Perrigo has seen positive trends in market share across its U.S. Store Brand OTC and notable European brands, supported by innovative strategies and marketing efforts.

Business Segment Analysis

In terms of segment performance:

• - Self Care: Reported net sales were $613 million, down 3.2% year-over-year. The segment saw a decline in consumption that affected inventory positioning ahead of the cold and allergy season.
• - Specialty Care: Faced a 4.6% decrease in net sales, although products like ellaOne® for Women's Health saw strong growth.
• - Infant Formula: Experience a significant 9.6% drop in sales, reflecting lower contract manufacturing volumes.

Despite these adverse developments, the segment labeled 'All Other,' primarily representing Oral Care, experienced a remarkable increase in adjusted operating income, highlighting the company’s improved operational productivity.

Cash Flow and Future Outlook

Perrigo's net cash from operating activities reached $96 million this quarter, while capital expenditures totaled $18 million. Moreover, the company returned $40 million to shareholders through dividends.

As Perrigo moves forward, the decision to divest the Infant Formula business is anticipated to bolster the company's financial positioning. The divestiture is proposed to deliver up to $175 million in total consideration, which includes $40 million upon closing and further contingent earnings tied to sales milestones until 2030.

Concluding Thoughts

As Perrigo adapts to a challenging consumer environment, it remains committed to leveraging its strengths within the self-care product sector. The company's anticipated simplification and focus on core offerings appear strategically sound for achieving consistent growth. Management is optimistic about the ongoing execution of its Three-S plan, expecting it to bring forth improved consistency in profitability and overall operational effectiveness in the longer term.